Objective. Current approaches offer no cures for rheumatoid arthritis (RA). Accumulating evidence has revealed that manipulation of bone marrow-derived mesenchymal stem cells (BM-MSCs) may have the potential to control or even prevent RA, but BM-MSCbased therapy faces many challenges, such as limited cell availability and reduced clinical feasibility. This study in mice with established collagen-induced arthritis (CIA) was undertaken to determine whether substitution of human gingiva-derived mesenchymal stem cells (G-MSCs) would significantly improve the therapeutic effects.
arthrodial joints (1) . Clinical drug development for treatment of RA has progressed slowly. Currently, only ϳ50% of RA patients show a response to treatment with most of the available products, such as tumor necrosis factor (TNF) inhibitors, interleukin-1 (IL-1) antagonists, and anti-IL-6 receptor antibody. None of these treatments are curative for RA (1) . Therefore, novel approaches to cure this disease are sorely needed.
Mesenchymal stem cells (MSCs) can exhibit immunomodulatory effects. They inhibit T cell proliferation in mixed lymphocyte cultures, prolong skin allograft survival, and decrease graft-versus-host disease (GVHD) when cotransplanted with hematopoietic stem cells (2) . These properties make them well-suited to serve as a candidate for a new approach in the prevention and treatment of allograft rejection, GVHD, and other autoimmune diseases. Bone marrow-derived MSCs (BM-MSCs) have been considered as a potential strategy in clinical cell therapy; however, there are some drawbacks and limitations to their clinical feasibility, such as the difficulty in obtaining sufficient cell numbers for therapeutic use.
Findings of a recent study confirmed that gingivaderived MSCs (G-MSCs), a population of stem cells that exists in the human gingival tissue (3), have several advantages over BM-MSCs. G-MSCs are easy to isolate, are homogeneous, and proliferate more rapidly than BM-MSCs (4). In addition, G-MSCs display stable morphologic and functional characteristics at higher passage numbers and are not tumorigenic (4) . Although G-MSCs demonstrate beneficial effects in preventing experimental colitis (3) and mitigating chemotherapyinduced oral mucositis (5) , utilization of G-MSCs for the treatment of autoimmune arthritis and other immune diseases has not been explored.
Recent studies have demonstrated that adoptive transfer of MSCs can up-regulate CD4ϩCD25ϩFoxP3ϩ Treg cells in vivo (6, 7) . Treg cells play an important role in the prevention and control of experimental autoimmune arthritis, an animal model that shares many of the features of RA (8, 9) . However, it is less clear what role Treg cells may play in the suppressive effect of MSCs on immune responses. Deaglio and colleagues demonstrated that the coexpression of CD39 (NTPDase1) and CD73 (ecto-5Ј-nucleotidase) in Treg cells contributes to their inhibitory function (10) . CD39 promotes the hydrolysis of ATP and ADP to generate AMP, which is then hydrolyzed by CD73 to adenosine. ATP is an important signaling molecule involved in many biologic processes, including immune responses. Although MSCs are known to express CD73, it is unclear whether they also express CD39, and it remains to be determined whether either of these ectoenzymes participates in the immunoregulatory function of MSCs.
In the present study, we demonstrate that G-MSCs can significantly attenuate inflammatory arthritis in an experimental collagen-induced arthritis (CIA) model. The therapeutic effects of G-MSCs appear to be mainly dependent on CD39/CD73 signals. We also found that their effects are dependent, at least in part, on the in vivo induction and expansion of Treg cells, a cell type that has been recognized as playing an important role in controlling autoimmunity (11) (12) (13) (14) . These results imply that manipulation of G-MSCs may provide a promising therapeutic approach for the treatment of patients with RA and other autoimmune diseases.
MATERIALS AND METHODS
Mice. DBA/1J mice (all female, ages 8-10 weeks) were obtained from The Jackson Laboratory. C57BL/6 mice transfected with a green fluorescent protein (GFP)-FoxP3 reporter construct (C57BL/6-FoxP3 gfp mice) were generously provided by Dr. Talil Chatilla (University of Southern California, Los Angeles). DBA/1J-FoxP3 gfp mice were produced by backcrossing C57BL/6-Foxp3 gfp mice with DBA/1J mice for 8-10 generations. All experiments using mice were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee at the University of Southern California.
Induction of arthritis. Bovine type II collagen (CII) was extracted and purified from bovine articular cartilage according to established protocols. CII was emulsified with an equal volume of Freund's complete adjuvant (CFA) containing 4 mg/ml heat-denatured Mycobacterium (Chondrex). DBA/1J mice or DBA/1J-Foxp3 gfp mice were immunized via intradermal injection at the base of the tail with 50 l of emulsion (100 g CII/mouse). To determine intervention effects, mice received a single intravenous injection of 2 ϫ 10 6 G-MSCs on day 14 after immunization. Alternatively, a similar dose of human dermal fibroblasts (a cell line from American Type Culture Collection) was injected intravenously as a control. To deplete CD4ϩCD25ϩFoxP3ϩ Treg cells, mice were treated intraperitoneally (IP) with 0.25 mg of anti-CD25 antibody (clone PC61) 7 days after CII immunization.
Evaluation for clinical arthritis. Clinical signs of arthritis were evaluated every 2-3 days after immunization to determine arthritis incidence. Each paw was evaluated and scored individually for severity of arthritis using a previously described scoring system (scale 0-4) (15) (16) (17) . The scores for each paw were summed to yield a total arthritis severity score per mouse, with a maximum score of 16 for each animal. Each paw score was judged as follows: 0 ϭ no signs of arthritis, 1 ϭ mild swelling confined to the tarsal bones or ankle joint, 2 ϭ mild swelling extending from the ankle to the tarsal bones, 3 ϭ moderate swelling extending from the ankle to the metatarsal joints, and 4 ϭ severe swelling encompassing the ankle, foot, and digits, or ankylosis of the limb.
Histopathologic evaluation of the joints. After the mice were killed on day 60, the hind limbs were collected. Following routine fixation, decalcification, and paraffin em-bedding, tissue sections were prepared and stained with hematoxylin and eosin. All slides were evaluated by investigators who were blinded with regard to the experimental conditions. The extent of synovitis, pannus formation, and bone/cartilage destruction was determined using a graded scale, as follows: grade 0 ϭ no signs of inflammation, 1 ϭ mild inflammation with hyperplasia of the synovial lining without cartilage destruction, 2-4 ϭ increasing degrees of inflammatory cell infiltration and cartilage/bone destruction.
Flow cytometric analysis. Ice-cooled single-cell suspensions were prepared from trypsinized G-MSC cultures, G-MSCs cocultured with mouse T cells, or mouse lymphoid organs. For G-MSC phenotype identification, we used antibodies directed against human CD11b, CD29, CD45, CD73, CD86, CD90, class II major histocompatibility complex (MHC), or isotype-matched control IgG (all from BD PharMingen), and against human CD31, CD34, CD44, CD105, class I MHC, or isotype-matched IgG (all from eBioscience). Antibodies against CD4 (RM4-5), interferon-␥ (IFN␥), IL-4, and IL-17 were from eBioscience. Antibodies to Helios and CD39 were from Biolegend. Synovial fluid from 2 knee joints of each mouse with arthritis was collected and flushed out using 10 ml phosphate buffered saline via a 25-gauge needle. This method usually yields 1-6 ϫ 10 4 cells from normal mice and 3-10 ϫ 10 4 cells from arthritic mice. For evaluation of mouse Treg cells in vivo, results were obtained on a BD FACSCalibur flow cytometer and analyzed using FlowJo.
Cytokine analysis. T cells were isolated from the spleens and draining lymph nodes of arthritic mice on day 60 after CII immunization, and then stimulated in vitro with phorbol myristate acetate (PMA) (50 ng/ml) and ionomycin (500 ng/ml) for 5 hours, with brefeldin A (10 g/ml) (all from Calbiochem) for 4 hours, and intracellular expression of IL-4, IL-17, IFN␥, TNF␣, IL-2, and IL-10 was analyzed by flow cytometry.
Murine naive CD4؉ T cell differentiation in vitro. Naive CD4ϩCD25ϪCD62Lϩ T cells were purified from the spleens of DBA/1 mice via magnetic isolation (Miltenyi Biotec). G-MSCs were cocultured with naive CD4ϩCD25Ϫ CD62Lϩ T cells (1:25) during their in vitro differentiation into T helper cells. G-MSCs were allowed to adhere to the plate overnight before coculture. Naive CD4 cells were stimulated with anti-CD3 (2 g/ml) and anti-CD28 (2 g/ml) antibodies (both from Biolegend) in the presence of irradiated (30 cGy) syngeneic non-T cells, along with cytokines for Th1, Th2, or Th17 cell polarization differentiation, as previously described (18) . After 3 days in culture, differentiated cells were restimulated with PMA and ionomycin for 5 hours and brefeldin A for 4 hours. The expression of IFN␥, IL-4, and IL-17 was then measured by flow cytometry.
In vitro suppression assays. To examine the suppressive activity of G-MSCs in vitro, mouse splenic T cells, which were isolated from DBA/1J mice using nylon wool, or splenic CD4ϩCD25Ϫ cells, which were isolated from DBA/1J mice using magnetic isolation, were stimulated with anti-CD3 antibody (0.025 g/ml) and irradiated (30 cGy) antigen-presenting cells (APCs). G-MSCs were plated in triplicate in 96-well plates and allowed to adhere to the plate overnight. The ratio of G-MSCs to mouse CD4ϩCD25Ϫ T cells ranged from 1:1 to 1:200. Cells were cultured for 3 days and 1 Ci/well of 3 H-thymidine was added for the last 18 hours of culture, as previously reported (19) .
To assess the possibility that G-MSCs may induce mouse T cell death, CD4ϩCD25Ϫ T cells labeled with 5,6-carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen) were stimulated with soluble anti-CD3 antibody (0.025 g/ml) along with irradiated non-T cells as APCs (1:1). A gradient of G-MSCs was added to the CD4ϩCD25Ϫ T responder cells at a ratio of 1:1-1:200, and suppression of cycling CFSElabeled CD4ϩCD25Ϫ T cells was assessed on the gate of CFSE-labeled CD4ϩ cells negative for 7-aminoactinomycin D (7-AAD).
To determine the dependence of the suppressive function of G-MSCs on cell contact, a Transwell system was used. Briefly, these experiments were performed in 24-well Transwell plates with 0.4-m pore membranes (Corning Costar). Mouse CD4ϩCD25Ϫ cells (1 ϫ 10 6 ) and irradiated APCs (1 ϫ 10 6 ) were seeded to the upper compartment of the chamber, while G-MSCs (2 ϫ 10 5 ) were seeded to the lower compartment. Cells were cultured in the presence of anti-CD3 antibody for 72 hours and analyzed as described above.
In some experiments, mouse CD4ϩCD25Ϫ T cells were cocultured with G-MSCs (1:25) antibody (10 g/ml; BD PharMingen), or anti-IL-10 receptor antibody (anti-IL-10R) (10 g/ml; R&D Systems). Proliferation was determined with 3 H-thymidine incorporation. Statistical analysis. For comparison of treatment groups, we performed unpaired t-tests (Mann-Whitney), paired t-tests, and one-way or two-way analysis of variance (where appropriate). Comparisons of percentages were done using the chi-square test. All statistical analyses were performed using GraphPad Prism software (version 4.01). P values less than 0.05 were considered significant.
RESULTS

Suppression of mouse T cell proliferation and differentiation by G-MSCs through CD39/CD73 signals.
We and other investigators have recently shown that G-MSCs display immunomodulatory properties similar to those of human BM-MSCs, including inhibition of the activation and proliferation of human T cells (3, 4, 20, 21) . To determine whether G-MSCs have immunosuppressive effects on mouse CD4ϩ T lymphocytes in response to T cell receptor stimulation in vitro, we cocultured these cells and found that the G-MSCs inhibited the proliferation of mouse CD4ϩCD25Ϫ T cells in a dosedependent manner ( Figure 1A To explore the mechanisms responsible for G-MSC-mediated suppression of T cell proliferation, we analyzed several potential candidates. To this end, we found that G-MSCs inhibited mouse T cell proliferation via a process that is dependent on CD73 and CD39 signals. We also observed that the TGF␤, IDO, and prostaglandin E 2 (PGE 2 ) pathways were not involved ( Figure 1C ) (see also Supplementary Figure 1C , available on the Arthritis & Rheumatism web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.37894/abstract). As a control, we used a human epidermal fibroblast cell line that is also differentiated from MSCs (22) , to determine whether any fibroblast cell could mediate this suppression. We observed that human epidermal fibro- To rule out the possibility that human-derived gingival cells might kill murine T cells as a way to nonspecifically suppress T cell responses, we labeled murine T cells with CFSE and measured the inhibition of proliferation (CFSE dilution) of T responder cells by gating on CFSE-labeled CD4ϩ7-AADϪ live cells. We observed that in cultures with a G-MSC-to-T responder cell ratio of 1:25, there was 50% suppression of CD4ϩ T cell proliferation ( Figure 1A ), suggesting that cell killing was not the mechanism involved. Furthermore, G-MSCs, but not fibroblasts, also significantly inhibited the differentiation of mouse Th1, Th2, and Th17 cells in vitro ( Figures 1D and E) .
Decreased severity of experimental arthritis following treatment with G-MSCs. To determine the immunomodulatory role of G-MSCs in the context of autoimmune arthritis, we relied on the CIA model. We observed a significant delay in disease onset and a decrease in arthritis severity scores following a single injection of G-MSCs on day 14 after CII/CFA immunization (Figure 2A ). Histologic and quantitative analyses of the whole ankle joints demonstrated a significant decrease in synovitis, pannus formation, and destruction of bone and cartilage in G-MSC-treated mice compared with controls ( Figure 2B ). Because mouse skin fibroblasts have been shown to suppress the inflammatory response in a mouse model of autoimmune arthritis (23), we chose human skin fibroblasts as a control for the human-derived gingival stem cells. The human skin fibroblasts exhibited no protective effect in this mouse CIA model (Figures 2A and B) .
Down-regulation of the inflammatory responses in CIA following treatment with G-MSCs. We next investigated the mechanisms underlying the decrease in severity of CIA following administration of G-MSCs. Injection of G-MSCs into the tail vein of mice with CIA significantly reduced the percentage of cells secreting the proinflammatory cytokines IFN␥, IL-17, and TNF␣ in the draining lymph nodes ( Figure 2C ). G-MSCtreated mice also produced consistently lower percentages of Th1 and Th17 cells (Figures 2C and D) . In addition, G-MSC treatment decreased the production of IL-2 from mouse CD4ϩ effector T cells, but did not significantly change IL-10 production ( Figure 2C ). In contrast, cells producing Th2-type cytokines (IL-4, IL-5, and IL-13) were almost undetectable in this model, and G-MSC treatment did not alter their levels (results not shown).
Promotion of Treg cells in CIA following treatment with G-MSCs. Several studies have indicated that Treg cells confer significant protection against CIA by decreasing the activation and joint homing of autoreactive Th1 cells, and by inhibiting osteoclastogenesis (9, (24) (25) (26) . To determine the relationship between GMSCs and Treg cells in vivo, we first infused G-MSCs into naive DBA/1J-Foxp3 gfp mice. As shown in Figure  3A , treatment with G-MSCs significantly increased the frequency of CD4ϩFoxP3ϩ cells in the spleens and lymph nodes 1 week after injection in these mice. The Treg cell frequency reached a peak on day 11 after G-MSC infusion. However, the levels of Treg cells returned to baseline values 2 weeks after G-MSC injection in naive mice (results not shown).
We next investigated the dynamic effects of Treg cells in mice with CIA, again using FoxP3 gfp mice on the DBA/1J background. Consistent with previous findings showing that G-MSC treatment increased the expression of FoxP3 in the inflamed colon tissue of mice with Dextran sulfate sodium-induced experimental colitis (3), our results revealed that G-MSCs were also able to induce Treg cell responses in mice with CIA ( Figure  3B ). The percentage of cells expressing FoxP3 in the spleens and draining lymph nodes was significantly increased at 1 week and 3 weeks after G-MSC injection.
However, the increased FoxP3ϩ cell frequency in the spleens and draining lymph nodes gradually declined to levels that were similar to those in the control group by 5 weeks following cell infusion ( Figure 3B ). Interestingly, we began to observe a significant up-regulation of FoxP3ϩ cell frequency in the synovial fluid of mice with CIA 3 weeks after G-MSC infusion, although this increase was not observed in the early stages (Figures 3C  and D) .
Increased levels of induced Treg (iTreg) but not natural Treg (nTreg) cells following treatment with G-MSCs.
A study has recently revealed that expression of Helios, an Ikaros transcription factor family member, might distinguish thymus-derived nTreg cells from iTreg cells (27) (28) (29) . In our assessment of the phenotypes of increased FoxP3ϩ cells in G-MSC-treated mice with CIA, we found that the majority of the expanded Treg cell population was Helios negative ( Figure 4A ). Similarly, in the synovial fluid, most of the FoxP3ϩ cells did not express Helios (results not shown), suggesting that G-MSC treatment may induce the generation of new iTreg cells rather than the expansion of endogenous nTreg cells in CIA.
Given that a population of CD4ϩCD39ϩ cells, comprising TGF␤-producing FoxP3ϪCD39ϩCD4ϩ T cells and IL-10-producing FoxP3ϩCD39ϩCD4ϩ T cells, has been shown to have a regulatory function in the murine CIA model (30), we sought to investigate whether CD4ϩCD39ϩ T cells were affected by G-MSC treatment in our CIA model. We found that there was no alteration of the percentages and total numbers of CD4ϩCD39ϩ T cells after G-MSC treatment ( Figure  4B Figures 4C and D) . Taken together, these findings likely indicate that G-MSC treatment can selectively induce the Helios-negative CD4ϩFoxP3ϩCD39ϩ Treg cell subset in CIA.
In vivo role of Treg cells in the suppressive effect of G-MSCs on CIA. Because we had observed that Treg cells play an important role in controlling CIA progression, we next investigated whether the effects of G-MSC treatment are dependent on the function of Treg cells. To determine this, Treg cells were depleted in arthritic mice by IP administration of PC61, an anti-CD25 anti-body. Levels of CD4ϩFoxP3ϩ Treg cells in the spleens decreased significantly 1 week after PC61 administration. Treg cell depletion was maintained for 4 weeks, and thereafter starting at 5 weeks after PC61 treatment, the Treg cell levels began to be restored ( Figure 5A ).
We then determined the role of Treg cells in the G-MSC-mediated suppression of CIA. Treatment with PC61 resulted in an accelerated incidence of arthritis ( Figure 5B ), significantly increasing arthritis severity scores ( Figure 5B), and severe histologic damage to the joint ( Figure 5C ). G-MSC injection in combination with PC61 treatment delayed the onset and reduced the severity of arthritis when compared to PC61 treatment alone ( Figure 5B ). However, compared to G-MSC treatment alone, the combination of G-MSC and PC61 treatment led to a significantly greater severity of arthritis ( Figure 5B) , suggesting that the depletion of Treg cells in vivo partially attenuated the protective effect of the G-MSCs. Similarly, combined treatment with G-MSCs and PC61 produced lower frequencies of Th1 and Th17 cells as compared to treatment with PC61 alone, and produced significantly higher percentages of IFN␥-producing and IL-17-producing cells as compared to treatment with G-MSC alone ( Figure 5D ).
Taken together, these findings suggest that G-MSC treatment in mice can still protect against arthritis after Treg cell depletion. However, the therapeutic effect of G-MSCs was significantly less pronounced under conditions of Treg cell depletion compared to conditions in which Treg cells remain intact. Thus, the G-MSC-mediated immunoregulatory function in vivo may be attributed to Treg cells, but could also be attributed to other mechanisms.
Dependency of G-MSC-mediated suppression of CIA on CD39 and CD73 signals. We next sought to identify the kinds of mechanisms involved in the functions of G-MSCs. Consistent with previous studies (31,32) , we showed that G-MSCs were homogeneously positive for the mesenchymal markers CD29, CD44, and CD105, negative for the hematopoietic markers CD34 and CD45 and the endothelial cell marker CD31, and negative for the costimulating molecule CD86 ( Figure  6A ). Furthermore, positivity for CD39 and positivity for CD73 were also found to be phenotypic characteristics of G-MSCs ( Figure 6A ).
As noted earlier ( Figure 1B) , we observed that G-MSCs inhibited mouse T cell proliferation via CD39 and CD73 signals. It has been reported that pretreatment of G-MSCs with the COX inhibitor indomethacin will significantly reverse the inhibitory effect of G-MSCs on dendritic cell differentiation and cytokine secretion in vitro, and that these cells will lose their capacity to attenuate contact hypersensitivity after injection into mice in vivo (21) . Moreover, overnight treatment with indomethacin can maintain these effects on G-MSCs for at least 1 week (21). Previous observations of CD39 and CD73 expression levels in mouse T cells (33, 34) suggest that it is not feasible to treat mice with CD39 and CD73 inhibitors because of their pleiotropic effects. Therefore, in order to determine whether CD39 and/or CD73 signals are involved in the mechanism of G-MSC protection against CIA in mice, we pretreated G-MSCs with 100 M POM-1 (a CD39 inhibitor) or 100 M APCP (a CD73 inhibitor) overnight in vitro, and then injected these cells into arthritic mice.
Following pretreatment with POM-1 and APCP, Figure 6B ) and increased severity of arthritis ( Figure 6C ), suggesting that both CD39 and CD73 are important in the G-MSC-mediated control of T cell-mediated diseases.
We next investigated the role of CD39 and CD73 signals in the G-MSC-mediated up-regulation of Treg cells in vivo. To address this, we treated G-MSCs with the CD39 inhibitor and CD73 inhibitor overnight, and then infused G-MSCs into mice with CIA. At 1 week following infusion, the FoxP3ϩ Treg cell frequency in the G-MSC-treated group was identical to that in the control group ( Figure 6D ), indicating that pretreatment of G-MSCs with CD39 or CD73 inhibitors results in the abrogation of their ability to increase Treg cell frequencies and to protect against the progression of CIA.
DISCUSSION
MSCs represent a variety of stromal cells that have the potential to self-renew and differentiate. The immunosuppressive function of MSCs is ascribed to their inhibitory effects on T cells and other immune cells, including dendritic cells and natural killer cells in vitro (35, 36) . It has been reported that human BMMSCs strongly suppress T lymphocyte proliferation via mechanisms that do not involve the induction of T cell apoptosis, but are likely due to the production of soluble factors, including hepatocyte growth factor (37), PGE 2 (38), HO-1 (39), TGF␤1, and NO (7) . In this study, we observed that G-MSCs suppress mouse T cell responses, and that cell contact is not necessary for this suppression, suggesting that soluble factors are involved in this mechanism. However, to our knowledge, this is the first study to show that G-MSCs inhibit mouse T cell proliferation via CD39 and/or CD73 signals, but not via IL-10, NO, IDO, PGE 2 , or TGF␤1, in vitro. The species used as a source of cells may have led to the different results.
Extracellular and/or immediate pericellular accumulation of adenosine, released by damaged cells as an indicator of trauma and cell death, elicits immunosuppressive cellular responses that are mediated through several type 1 purinergic (adenosine) receptors, including the A 2A adenosine receptor (10, 40) . The activation of A 2A -mediated signals can attenuate T cell-mediated experimental colitis by suppressing the expression of proinflammatory cytokines in a manner independent of both IL-10 and TGF␤ (41) . Recent studies show that coexpression of CD39 and CD73 on CD4ϩCD25ϩ FoxP3ϩ Treg cells, which catalyzes the sequential generation of adenosine by degradation of extracellular ATP/ADP to 5Ј-AMP (CD39) and conversion of 5Ј-AMP to adenosine (CD73), leads to strong downregulation of T cell proliferation and a decreased secretion of proinflammatory cytokines (10, 34, 40) . Herein, we demonstrated that G-MSCs express CD39 and CD73, thus supporting the generation of adenosine and thereby promoting strong immunosuppression of effector T cells in vitro and in vivo. G-MSCs not only can promote the up-regulation of FoxP3ϩ Treg cells and the possible migration of these cells in inflammatory disease in vivo, but also may share part of the mechanisms of immunosuppressive functions indirectly via adenosine.
G-MSCs may directly or indirectly suppress CIA. Since G-MSCs express CD39 and CD73 and since both 5Ј-AMP and adenosine have a potent immunosuppressive activity, it is reasonable to expect that G-MSCs will suppress CIA in a CD39-or CD73-dependent manner. However, G-MSCs may also promote Treg cells through CD39 and CD73 signaling, since pretreatment of G-MSCs with CD39 or CD73 inhibitors abrogated G-MSC-mediated Treg cell up-regulation. We have demonstrated that the suppressive effect of G-MSCs on CIA is dependent, at least in part, on Treg cells, supporting the theory that G-MSCs exert their immunosuppressive function via direct suppression of inflammatory cell responses and via an indirect immunoregulatory function, involving increased induction of Treg cells.
Multiple studies have shown that the immunoregulatory function of MSCs is associated with upregulated expression of Treg cells in vivo (6, 7, 42) . Recently, a population of CD4ϩCD39ϩ T cells was identified as having a regulatory function in the CIA model. This subset is composed of TGF␤-producing FoxP3Ϫ CD39ϩCD4ϩ T cells and IL-10-producing FoxP3ϩ CD39ϩCD4ϩ T cells, each of which plays an important role in autoimmune diseases (30) . Our results suggest that G-MSCs selectively promote the production of the FoxP3ϩCD39ϩCD4ϩ Treg cell subset in naive mice and in the proinflammatory CIA disease model. Although it is arguable whether Helios can distinguish nTreg from iTreg cells, our data suggest that Helios-negative FoxP3ϩCD39ϩ T cells are a newly identified cell population that may be induced in CIA.
Although the frequency of Treg cells was increased temporarily in naive mice, it is notable that treatment with G-MSCs sustained the increased expression of CD39ϩFoxP3ϩ Treg cells in CIA. It is unknown whether the inflammatory environment affects the function of G-MSCs. Interestingly, whereas the increased Treg cell frequency in the spleens and lymph nodes gradually declined, the increased frequencies of 
